GD
GDTC.US CytoMed Therapeutics Limited Ordinary Shares
- Market cap
- USD 9.90M
- P/E
- -
- P/B
- 2.60x
- ROE
- -106.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GDTC.US undervalued?
Graham numberThe Graham number of CytoMed Therapeutics Limited Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CytoMed Therapeutics Limited Ordinary Shares fundamental analysis
No fundamental analysis for CytoMed Therapeutics Limited Ordinary Shares yet.
CytoMed Therapeutics Limited Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also deve…
Full company profileCytoMed Therapeutics Limited Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CytoMed Therapeutics Limited Ordinary Shares annual financial statements (SGD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 44.9K | 84.2K | 366K | 509K | 69.5K | 324K | 693K |
| Gross Profit | - | 54.8K | 110K | -109K | -4.36M | 52.4K | 256K | -3.77M |
| Operating Income | -652K | -1.33M | -1.16M | -2.34M | -4.36M | -3.60M | -4.79M | -5.22M |
| EBITDA | -429K | -1.04M | -1.56M | -2.61M | -3.70M | -2.17M | -3.57M | -4.66M |
| Net Income | -859K | -1.94M | -2.07M | -3.13M | -4.13M | -2.52M | -3.98M | -5.31M |
| EPS | -0.15 | -0.33 | -0.30 | -0.40 | -0.39 | -0.22 | -0.34 | -0.45 |
| Balance Sheet | ||||||||
| Total Assets | 2.94M | 3.82M | 6.10M | 5.25M | 12.4M | 10.1M | 7.98M | 7.01M |
| Total Liabilities | 1.01M | 3.35M | 3.50M | 4.66M | 1.13M | 1.02M | 1.13M | 1.61M |
| Shareholders' Equity | 1.94M | 477K | 2.60M | 590K | 11.3M | 8.96M | 6.54M | 4.97M |
| Cash & Short-term Investments | 459K | 931K | 2.53M | 1.59M | 9.02M | 4.97M | 2.10M | 1.46M |
| Total Debt | 675K | 2.99M | 3.27M | 4.24M | 449K | 463K | 483K | 454K |
| Cash Flow | ||||||||
| Operating Cash Flow | -641K | -916K | -1.72M | -1.40M | -3.54M | -2.71M | -3.70M | -4.96M |
| Capital Expenditure | 1.19M | 245K | 584K | 476K | 58.5K | 1.40M | 703K | 560K |
| Free Cash Flow | -1.83M | -1.10M | -2.30M | -1.88M | -3.60M | -4.11M | -4.40M | -5.52M |
| Ratios | ||||||||
| ROE | -44.4% | -407.1% | -79.8% | -531.0% | -36.7% | -28.1% | -60.8% | -106.9% |
| ROA | -29.2% | -50.8% | -34.0% | -59.6% | -33.3% | -25.0% | -49.8% | -75.8% |
| Net Profit Margin | - | -4,323.2% | -2,463.4% | -856.4% | -811.8% | -3,621.1% | -1,227.1% | -765.9% |
| Debt to Equity | 0.35x | 6.26x | 1.26x | 7.19x | 0.04x | 0.05x | 0.07x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CytoMed Therapeutics Limited Ordinary Shares dividends
CytoMed Therapeutics Limited Ordinary Shares has not paid dividends in the last 7 fiscal years.
Who owns CytoMed Therapeutics Limited Ordinary Shares
- Insiders 70.49%
- Institutions 0.59%
- Public & others 28.92%
- Shares outstanding 11.9M
- Free float 3.52M
Top funds holding GDTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 4.85K | 0.04% | 0.00% | Aug 2026 |
Top institutions holding GDTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Axiom Investment Management LLC | 7.03K | 0.06% | 0.00% | Jun 2026 |
| UBS Group AG | 4.83K | 0.04% | -21.85% | Jun 2026 |
| Advisor Group Holdings, Inc. | 21.00 | 0.00% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
CytoMed Therapeutics Limited Ordinary Shares company profile
- Company name
- CytoMed Therapeutics Limited Ordinary Shares
- Ticker
- GDTC.US
- ISIN
- SGXZ17669631
- Exchange
- USA Stocks
- Listed since
- Apr 14, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 42
- Fiscal year end
- December
- Address
- 1 Commonwealth Lane, Singapore, Singapore, 149544
- Phone
- 65 6250 7738
- Website
- w2.cytomed.sg
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
CytoMed Therapeutics Limited Ordinary Shares management
5- Mr. Chee Kong ChooExecutive Chairman · born 1958
- Dr. Jieming Zeng M.D., Ph.D.Chief Scientific & Medical Officer and Director · born 1974
- Ms. Yvonne GohChief Financial Officer · born 1990
- Dr. Tien Wee Luk M.D.Chief Clinical Officer · born 1984
- Ms. Yoong Ying TanChief Corporate Officer · born 1989